文献速递内脏/肾动脉与血管畸形

肠系膜动脉支架内再狭窄:再置入支架与单纯球囊扩张的再干预率比较

Reintervention Rates for Restenting Versus Angioplasty Alone in Mesenteric Artery In-Stent Restenosis.
PubMed 文献 · Ann Vasc Surg · 2025-07-22

再置入支架组1年内再干预显著少于单纯球囊扩张组(HR 0.13,95%CI 0.03–0.50,P=0.003),围术期并发症低。

要点

  • 再置入支架较单纯球囊扩张显著降低1年内再干预风险(HR 0.13)。
  • 肠系膜动脉支架内再狭窄腔内再干预技术成功率高、围术期并发症低。
  • 再置入支架组术后更少报告慢性肠系膜缺血症状。

核心结论

  • 肠系膜动脉支架内再狭窄的腔内再干预技术成功率高且围术期并发症低。
  • 再置入支架组1年内再干预显著少于单纯球囊扩张组(HR 0.13,95%CI 0.03–0.50,P=0.003)。
  • 再置入支架组术后更可能无慢性肠系膜缺血症状。

研究设计与样本

  • 回顾性队列研究,纳入2008至2021年Cleveland Clinic Health System连续因肠系膜动脉支架内再狭窄行腔内干预的患者。
  • 单纯球囊扩张21条血管(38.8%),再置入支架33条血管(61.2%);中位临床随访21个月。
  • 采用单变量分析和Cox比例风险模型识别早期再干预预测因素。

主要发现

  • 再置入支架组1年内再干预少于单纯球囊扩张组,风险比0.13(95%CI 0.03–0.50),P=0.003。
  • 单变量分析中无其他临床或手术因素可预测12个月再干预。
  • 再置入支架组术后更可能否认任何慢性肠系膜缺血症状。

临床怎么用

  • 对肠系膜动脉支架内再狭窄行腔内再干预时,再置入支架可能较单纯球囊扩张降低1年内再干预风险。
  • 该结果支持在合适患者中优先考虑再置入支架策略,但需结合个体情况。

局限性

  • 非随机分组,存在选择偏倚可能。
  • 中位随访21个月,仅评估1年再干预结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mesenteric artery in-stent restenosis (MAISR) is a common complication of endovascular interventions for mesenteric ischemia and the major cause of treatment failure. The objective of this study was to characterize the spectrum of endovascular interventions performed for MAISR at a large academic center and to compare 1-year clinical outcomes between the major treatment groups, angioplasty, and stenting to identify predictors of early reintervention. METHODS: Consecutive patients undergoing endovascular intervention for MAISR from 2008 to 2021 in the Cleveland Clinic Health System were identified. Electronic medical records and imaging were reviewed. Univariable and Cox proportional hazard models were used to identify predictors of early reintervention. RESULTS: Forty-eight patients (54 vessels) required intervention for MAISR. The mean age was 70 years and 36 (66.7%) were female. Angioplasty without stenting was performed in 21 treated vessels (38.8%). Restenting was performed in 33 vessels (61.2%). Median clinical follow-up was 21 months. Restenting had fewer reinterventions over 1 year compared to angioplasty alone [hazard ratio 0.13 (95% confidence interval: 0.03, 0.50), P = 0.003]. No other clinical or operative factors were predictive of reintervention at 12 months in univariable analysis. CONCLUSION: Endovascular reintervention for MAISR is associated with a high technical success rate and low perioperative morbidity. Patients who were restented in this cohort were more likely to deny having any symptoms of chronic mesenteric ischemia postintervention, and restenting had fewer reinterventions in the first year compared to angioplasty alone.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Taaffe JP, Alexander A, Smith AH, et al. Reintervention Rates for Restenting Versus Angioplasty Alone in Mesenteric Artery In-Stent Restenosis. Ann Vasc Surg. 2025. PMID: 40706844. doi:10.1016/j.avsg.2025.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。